Редкие иммуноопосредованные нежелательные явления: обзор литературы


DOI: https://dx.doi.org/10.18565/pharmateca.2020.7.8-14

Е.А. Дегтярёва, С.А. Проценко, Е.Н. Имянитов

Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова, Санкт-Петербург, Россия
Открытие ингибиторов контрольных точек иммунного ответа знаменовало новую эру в лечении злокачественных новообразований, значительно увеличив продолжительность жизни больных. В свою очередь за счет активации иммунного ответа применение анти-CTLA-4- и анти-PD-1/PD-L1-моноклональных антител ассоциировано с развитием уникального спектра осложнений – иммуноопосредованных нежелательных явлений. Патологический процесс может затрагивать любой орган и систему, но наиболее часто поражаются кожа, желудочно-кишечный тракт, печень, легкие и железы внутренней секреции. В последнее время неуклонно растет число нетипичных иммуноассоциированных состояний, в т.ч. и жизнеугрожающих, что требует своевременного их выявления и адекватного лечения. В данной статье описаны редкие осложнения иммунотерапии, а также их диагностика и купирование.
Ключевые слова: иммунотерапия, ингибиторы контрольных точек иммунного ответа, анти-CTLA-4-моноклональные антитела, анти-

Литература


1. Schoenfeld S.R., Aronow M.E., Leaf R.K., et al. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020;25(1):6–14. Doi: 10.1634/theoncologist.2019-0083.


2. Kim J.M., Materin M.A., Sznol M., et al. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology. 2019;126(7):1058–62. Doi: 10.1016/j.ophtha.2019.01.031.


3. Fang T., Maberley D.A., and Etminanb M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31(3):319–22. Doi: 10.1016/j.joco.2019.05.002.


4. Michel L., Rassaf T., Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. IJC Heart & Vasculature. 2019;25:100420. Doi: 10.1016/j.ijcha.2019.100420.


5. Agrawal N., Khunger A., Vachhani P., et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. Case Rep Oncol. 2019;12:260–76. Doi: 10.1159/000498985.


6. Johnson D.B., Balko J.M., Compton M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55. Doi: 10.1056/NEJMoa1609214.


7. Mahmood S.S., Fradley M.G., Cohen J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. Doi: 10.1016/j.jacc.2018.02.037.


8. Moslehi J.J., Salem J.E., Sosman J.A., et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2019; 391(10124):933. Doi: 10.1016/s0140-6736(18)30533-6.


9. Upadhrasta S., Elias H., Patel K., et al. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5(1):6–14. Doi: 10.1016/j.cdtm.2019.02.004.


10. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Management of Immunotherapy-Related Toxicities, Version 1.2020 – December 16, 2019. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf on Februrary 25, 2020.


11. Curigliano G., Lenihan D., Fradley M., et al. Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations. Ann Oncol. 2020;31(2):171–90. Doi: 10.1016/j.annonc.2019.10.023.


12. Saade A., Mansuet-Lupo A., Arrondeau J., et al. Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer. 2019;7:266. Doi: 10.1186/s40425-019-0760-4.


13. Khan A., Zhang H., Chen C., et al. Impact of pericardial effusion for patients receiving immune checkpoint inhibitors. J Clin Oncol. 2019;37:e14121-e14121. Doi: 10.1200/JCO.2019.37.15_suppl.e14121.


14. Shaheen S., Mirshahidi H., Nagaraj G., et al. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol 2018;7:11. Doi: 10.1186/s40164-018-0104-y.


15. Chen D.Y., Huang W.K., Chien-Chia Wu V., et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immunooncology. J Formos Med Assoc. 2019;pii:S0929-6646(19)30408-5. Doi: 10.1016/j.jfma.2019.07.025.


16. Ederhy S., Cautela J., Ancedy Y., et al. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging 2018;11(18):1187–90. Doi: 10.1016/j.jcmg.2017.11.036.


17. Lyon A.R., Yousaf N., Battisti N.M.L., et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–e458. Doi: 10.1016/S1470-2045(18)30457-1.


18. Cautela J., Rouby F., Salem J.E., et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol 2020;36(4):476–81. Doi: 10.1016/j.cjca.2019.11.035.


19. Al-Kindi S.G., Oliveira G.H. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc 2016;91(1):81–3. Doi: 10.1016/j.mayocp.2015.09.009.


20. Gelsomino F., Fiorentino M., Zompatori M., et al. Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann. Oncol. 2018;29(1):284–86. Doi: 10.1093/annonc/mdx718.


21. Daxini A., Cronin K. and Sreih A.G. Vasculitis associated with immune checkpoint inhibitors –a systematic review. Clin Rheumatol. 2018;37:2579–84. Doi: 10.1007/s10067-018-4177-0.


22. Jamal S., Hudson M., Fifi-Mah A., et al. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. 2020;47:166–75. Doi:10.3899/jrheum.190084.


23. Reynolds K.L., Guidon A.C. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 2019;24(4):435–43. Doi: 10.1634/theoncologist.2018-0359.


24. Connolly C., Bambhania K. and Naidoo J. Immune-Related Adverse Events: A Case-Based Approach. Front Oncol. 2019;9:530. Doi: 10.3389/fonc.2019.00530.


25. Möhn N., Beutel G., Gutzmer R., et al. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy–Review of the Literature and Future Outlook. J Clin Med. 2019;8(11):1777. Doi: 10.3390/jcm8111777.


26. Cuzzubbo S., Javeri F., Tissier M., et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 2017;73:1–8. Doi: 10.1016/j.ejca.2016.12.001.


27. Johnson D.B., Manouchehri A., Haugh A.M., et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2020;7(1):134. Doi: 10.1186/s40425-019-0617-x.


28. Safa H., Johnson D.H., Trinh V.A., et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319. Doi: 10.1186/s40425-019-0774-y.


29. Gravbrot N., Scherer K. and Sundararajan S. Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature. Case Rep Oncol Med. 2019;2019:5490707. Doi: 10.1155/2019/5490707.


30. Gaudy-Marqueste C., Monestier S., Franques J., et al. A severe case of ipilimumab-induced Guillain-Barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36(1):77–8. Doi: 10.1097/CJI.0b013e31827807dd.


31. Bhatia S., Huber B.R., Upton M.P., et al. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009;32(2):203–5. Doi: 10.1097/CJI.0b013e318193a206.


32. Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–68. Doi: 10.1200/JCO.2017.77.6385.


33. Haanen J., Carbonnel F., Robert C., et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–42. Doi: 10.1093/annonc/mdx225.


Об авторах / Для корреспонденции


Автор для связи: Е.А. Дегтярёва, врач-онколог, аспирант научного отдела инновационных методов терапевтической онкологии и реабилитации, НМИЦ онкологии им. Н.Н. Петрова, Санкт-Петербург, Россия; e-mail: degtyarevaekaterina@mail.ru 
Адрес: 197758, Россия, Санкт-Петербург, пос. Песочный, Ленинградская ул., 68


ORCID:
Е.А. Дегтярёва, ORCID: https://orcid.org/0000-0001-8533-1770 
С.А. Проценко, ORCID: https://orcid.org/0000-0002-5026-0009 
Е.Н. Имянитов, ORCID: https://orcid.org/0000-0003-4529-7891 


Бионика Медиа